{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:34:14Z","timestamp":1789533254583,"version":"build-2803163510"},"reference-count":5,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13760-024-02686-8","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T10:43:45Z","timestamp":1732531425000},"page":"553-555","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reversible posterior leukoencephalopathy syndrome (RPLS) in a patient with chronic lymphocytic leukemia (CLL) treated with Acalabrutinib, a Bruton\u2019s tyrosine kinase (BTK) inhibitor: a case report"],"prefix":"10.1007","volume":"125","author":[{"given":"Lise","family":"Janssens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Huybrecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie","family":"De Blauwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludo","family":"Vanopdenbosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heleen","family":"Parmentier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"2686_CR1","doi-asserted-by":"publisher","unstructured":"Fugate JE, Rabinstein AA (2015) Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol.;14(9):914\u2013925. doi: 10.1016\/S1474-4422(15)00111-8. Epub 2015 Jul 13. Erratum in: Lancet Neurol. 2015;14(9):874. https:\/\/doi.org\/10.1016\/S1474-4422(15)00195-7. PMID: 26184985","DOI":"10.1016\/S1474-4422(15)00195-7"},{"issue":"1","key":"2686_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13045-022-01302-7","volume":"15","author":"ST Chen","year":"2022","unstructured":"Chen ST, Azali L, Rosen L, Zhao Q, Wiczer T, Palettas M, Gambril J, Kola-Kehinde O, Ruz P, Kalathoor S, Rogers K, Kittai A, Grever M, Awan F, Byrd JC, Woyach J, Bhat SA, Addison D (2022) Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation. J Hematol Oncol 15(1):92. https:\/\/doi.org\/10.1186\/s13045-022-01302-7PMID: 35836241; PMCID: PMC9281099","journal-title":"J Hematol Oncol"},{"key":"2686_CR3","doi-asserted-by":"publisher","unstructured":"Langerbeins P (2022) Cardiotoxicity in patients treated with acalabrutinib. Blood.;140(20):2096\u20132097. https:\/\/doi.org\/10.1182\/blood.2022017791. PMID: 36394904","DOI":"10.1182\/blood.2022017791"},{"key":"2686_CR4","doi-asserted-by":"publisher","first-page":"1126235","DOI":"10.3389\/fphar.2023.1126235","volume":"14","author":"X Zou","year":"2023","unstructured":"Zou X, Zhou P, Lv W, Liu C, Liu J (2023) Posterior reversible encephalopathy syndrome after anlotinib treatment for small cell lung cancer: a case report and literature review. Front Pharmacol 14:1126235. https:\/\/doi.org\/10.3389\/fphar.2023.1126235PMID: 36814495; PMCID: PMC9939648","journal-title":"Front Pharmacol"},{"issue":"9","key":"2686_CR5","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/ph14090876","volume":"14","author":"YK Su","year":"2021","unstructured":"Su YK, Bamodu OA, Su IC, Pikatan NW, Fong IH, Lee WH, Yeh CT, Chiu HY, Lin CM (2021) Combined treatment with Acalabrutinib and Rapamycin inhibits glioma stem cells and promotes vascular normalization by downregulating BTK\/mTOR\/VEGF signaling. Pharmaceuticals (Basel) 14(9):876. https:\/\/doi.org\/10.3390\/ph14090876PMID: 34577576; PMCID: PMC8464793","journal-title":"Pharmaceuticals (Basel)"}],"updated-by":[{"DOI":"10.1007\/s13760-025-02933-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000}}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02686-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-024-02686-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-024-02686-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T06:46:20Z","timestamp":1762757180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-024-02686-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":5,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["2686"],"URL":"https:\/\/doi.org\/10.1007\/s13760-024-02686-8","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]},"assertion":[{"value":"13 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13760-025-02933-6","URL":"https:\/\/doi.org\/10.1007\/s13760-025-02933-6","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}